Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q2
$271M Sell
1,255,168
-122,400
-9% -$23.4M 0.05% 314
2026
Q1
$253M Sell
1,377,568
-13,802
-1% -$2.54M 0.05% 309
2025
Q4
$245M Sell
1,391,370
-47,838
-3% -$7.82M 0.05% 310
2025
Q3
$202M Sell
1,439,208
-304,001
-17% -$41.1M 0.04% 353
2025
Q2
$219M Buy
1,743,209
+232,823
+15% +$29M 0.04% 375
2025
Q1
$207M Sell
1,510,386
-23,427
-2% -$3.35M 0.05% 355
2024
Q4
$235M Buy
1,533,813
+381,122
+33% +$64.3M 0.05% 326
2024
Q3
$223M Buy
1,152,691
+18,905
+2% +$3.96M 0.06% 318
2024
Q2
$263M Buy
1,133,786
+161,643
+17% +$35.1M 0.08% 242
2024
Q1
$210M Sell
972,143
-42,440
-4% -$9.94M 0.07% 268
2023
Q4
$263M Sell
1,014,583
-50,935
-5% -$12.5M 0.1% 206
2023
Q3
$274M Sell
1,065,518
-49,084
-4% -$13.1M 0.12% 167
2023
Q2
$310M Hold
1,114,602
0.15% 141
2023
Q1
$310M Buy
1,114,602
+20,411
+2% +$5.65M 0.15% 141
2022
Q4
$303M Sell
1,094,191
-22,265
-2% -$6.29M 0.16% 142
2022
Q3
$298M Sell
1,116,456
-40,807
-4% -$8.67M 0.17% 131
2022
Q2
$236M Sell
1,157,263
-6,049
-0.5% -$1.24M 0.12% 177
2022
Q1
$245M Buy
1,163,312
+4,010
+0.3% +$872K 0.11% 210
2021
Q4
$278M Sell
1,159,302
-85,684
-7% -$22M 0.11% 206
2021
Q3
$352M Buy
1,244,986
+106,513
+9% +$34.9M 0.15% 151
2021
Q2
$394M Sell
1,138,473
-21,311
-2% -$6.46M 0.17% 129
2021
Q1
$324M Sell
1,159,784
-30,613
-3% -$8.26M 0.14% 146
2020
Q4
$291M Sell
1,190,397
-139,251
-10% -$35.9M 0.14% 149
2020
Q3
$377M Buy
1,329,648
+20,877
+2% +$5.82M 0.2% 101
2020
Q2
$350M Buy
1,308,771
+214,313
+20% +$64.4M 0.21% 95
2020
Q1
$346M Sell
1,094,458
-12,893
-1% -$3.91M 0.25% 76
2019
Q4
$329M Sell
1,107,351
-51,798
-4% -$14.4M 0.2% 93
2019
Q3
$270M Sell
1,159,149
-221,230
-16% -$51.5M 0.18% 112
2019
Q2
$323M Buy
1,380,379
+84,065
+6% +$19.4M 0.23% 84
2019
Q1
$306M Buy
1,296,314
+152,648
+13% +$48.1M 0.23% 87
2018
Q4
$344M Sell
1,143,666
-309,228
-21% -$98.7M 0.3% 69
2018
Q3
$513M Buy
1,452,894
+351,238
+32% +$121M 0.38% 48
2018
Q2
$320M Buy
1,101,656
+100,390
+10% +$28.2M 0.25% 80
2018
Q1
$274M Buy
1,001,266
+168,497
+20% +$52.3M 0.22% 98
2017
Q4
$265M Buy
832,769
+40,922
+5% +$13.1M 0.22% 94
2017
Q3
$248M Sell
791,847
-37,297
-4% -$11M 0.23% 96
2017
Q2
$225M Sell
829,144
-625,734
-43% -$165M 0.22% 103
2017
Q1
$398M Sell
1,454,878
-8,514
-0.6% -$2.41M 0.41% 47
2016
Q4
$415M Sell
1,463,392
-65,653
-4% -$19.5M 0.47% 42
2016
Q3
$479M Buy
1,529,045
+390,906
+34% +$116M 0.52% 38
2016
Q2
$275M Buy
1,138,139
+13,189
+1% +$3.48M 0.31% 71
2016
Q1
$293M Buy
1,124,950
+166,534
+17% +$44M 0.34% 63
2015
Q4
$294M Sell
958,416
-176,084
-16% -$50.6M 0.33% 64
2015
Q3
$331M Sell
1,134,500
-31,912
-3% -$10.5M 0.37% 59
2015
Q2
$471M Sell
1,166,412
-5,067
-0.4% -$2.03M 0.45% 45
2015
Q1
$495M Sell
1,171,479
-53,191
-4% -$21M 0.48% 40
2014
Q4
$416M Sell
1,224,670
-689,255
-36% -$223M 0.4% 53
2014
Q3
$633M Buy
1,913,925
+43,307
+2% +$14.3M 0.63% 28
2014
Q2
$590M Buy
1,870,618
+106,552
+6% +$32.1M 0.6% 29
2014
Q1
$540M Buy
1,764,066
+141,599
+9% +$44.9M 0.58% 29
2013
Q4
$454M Sell
1,622,467
-484,079
-23% -$125M 0.52% 35
2013
Q3
$507M Sell
2,106,546
-120,323
-5% -$26.9M 0.63% 26
2013
Q2
$479M Buy
+2,226,869
New +$476M 0.62% 28

Other funds holding BIIB

UBS AM's BIIB Position: Q2 2026 in Review

UBS AM reduced its Biogen (BIIB) stake by 8.9% in Q2 2026, selling an estimated $23.4M and leaving 1,255,168 shares worth $271M. The position accounts for 0.05% of the portfolio, ranked #314.

UBS AM first reported a position in BIIB in Q2 2013 and has held it in 53 quarters since. The position peaked at $633M in Q3 2014. 1,043 funds tracked by Wall St. Rank hold BIIB as of Q2 2026.

  • UBS AM held 1,255,168 shares of Biogen worth $271M as of Q2 2026.
  • UBS AM sold 122,400 Biogen shares in Q2 2026, an estimated $23.4M.
  • Biogen made up 0.05% of UBS AM's portfolio in Q2 2026, its #314 holding.
  • UBS AM first reported a position in Biogen in Q2 2013 and has held it in 53 quarters since.
  • UBS AM's Biogen position peaked at $633M in Q3 2014.
  • 1,043 funds tracked by Wall St. Rank held Biogen as of Q2 2026.

Based on UBS AM's 13F filing for Q2 2026, filed 13 Aug 2026.